Collecting Information on Use of Redifferentiation Medications for Radioactive Iodine-Refractory Thyroid Cancer in Routine Care

What this Trial Is About

Researchers are collecting information on the use of redifferentiating medications as a standard treatment for patients with radioactive iodine RAI-refractory thyroid cancer. This study is a registry designed to learn more about how these medications are used in routine clinical care for this condition. It is an observational study focused on patients who have thyroid cancer that does not respond well to RAI treatment. Participants will undergo follow-up visits at intervals determined by their usual clinical care. During these visits, researchers will record how well patients tolerate the redifferentiating medications and any adverse events they experience. The study includes patients receiving these agents as part of their regular treatment, both prospectively and retrospectively, but excludes those receiving such agents within other clinical trials. Participants will be monitored for adverse events at every visit over a period of two years. Researchers will collect and review data on medication tolerance and side effects during these follow-up appointments. This ongoing observation aims to provide a clearer picture of outcomes for patients treated with redifferentiation agents in usual care settings.

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer